NewAmsterdam Pharma Company N.V.
NAMS53
$24.92arrow_drop_down0.20%-$0.04
High Growth
NAMS53
$24.92
arrow_drop_down0.20%Performance History
| Key Stats | |
|---|---|
| Open | $24.97 |
| Prev. Close | $24.97 |
| EPS | -2.21 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 24.54 | 25.88 |
| 52 Week Range | 5.63 | 26.35 |
| Ratios | |
|---|---|
| EPS | -2.21 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
About NewAmsterdam Pharma Company N.V. (NAMS)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Michael Harvey Davidson FACC, Facc., Facp., M.D.
- Headquarters
- Naarden
- Employees
- 22
- Exchange
- NASDAQ
Keep an eye on NewAmsterdam Pharma Company N.V.
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is NewAmsterdam Pharma Company N.V.'s (NAMS) price per share?
The current price per share for NewAmsterdam Pharma Company N.V. (NAMS) is $24.92. The stock has seen a price change of -$0.05 recently, indicating a -0.2% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for NewAmsterdam Pharma Company N.V. (NAMS)?
For NewAmsterdam Pharma Company N.V. (NAMS), the 52-week high is $26.35, which is 5.74% from the current price. The 52-week low is $5.63, the current price is 342.42% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is NewAmsterdam Pharma Company N.V. (NAMS) a growth stock?
NewAmsterdam Pharma Company N.V. (NAMS) has shown an average price growth of -6.65% over the past three years. It has received a score of 88 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying NewAmsterdam Pharma Company N.V. as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is NewAmsterdam Pharma Company N.V. (NAMS) stock price performance year to date (YTD)?
As of the latest data, NewAmsterdam Pharma Company N.V. (NAMS) has a year-to-date price change of 108.54%. Over the past month, the stock has experienced a price change of 30.95%. Over the last three months, the change has been 51.03%. Over the past six months, the figure is 24.04%.
help
Is NewAmsterdam Pharma Company N.V. (NAMS) a profitable company?
NewAmsterdam Pharma Company N.V. (NAMS) has a net income of -$160.27M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -85.89% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $12.76M, although specific revenue growth data is currently not available. The gross profit is $12.76M. Operating income is noted at -$165.73M. EBITDA information is currently not available.
help
What is the market capitalization of NewAmsterdam Pharma Company N.V. (NAMS)?
NewAmsterdam Pharma Company N.V. (NAMS) has a market capitalization of $2.3B. The average daily trading volume is 24.81, indicating the stock's liquidity and investor engagement.
News
NEWAMSTERDAM PHARMA
INDUCEMENT SHARE OPTIONS
NON-EXECUTIVE HIRE
LDL-C LOWERING THERAPY
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWAMSTERDAM PHARMA
INVESTOR CONFERENCES
BIOPHARMACEUTICAL COMPANY
LDL-C LOWERING THERAPIES
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September
COMPANY ANNOUNCEMENT
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HEALTH
INSIDER'S BUY/SELL
MANAGEMENT STATEMENTS
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLINICAL STUDY
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
DIRECTORS AND OFFICERS
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer